Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug hearings

This article was originally published in The Tan Sheet

Executive Summary

House Energy & Commerce Committee aims to act on several drug-related issues this fall, likely beginning with markup of drug reimportation bill in late September. Committee is writing bill currently and working with FDA on safety language. Senate drug reimportation language passed as part of generic drug bill (S 812) includes a provision requiring HHS certification. Commerce also is looking at third week of September for hearing on Hatch/Waxman issues, although date could slip back into October. Time will likely be an issue, however, as Congress is targeting Oct. 4 for adjournment...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094501

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel